Historically, liver graft rejection has raised great interest in the scientific community since it was the major barrier to successful implementation of liver transplantation (LT) and to the achievement of long-term survival rates. Thanks to discovery and introduction of potent immunosuppressive agents—namely calcineurin inhibitors (CNI), cyclosporine (CsA), and tacrolimus (TAC)—, control of acute rejection (AR) of the liver graft has become feasible, and current clinical focus has shifted to chronic rejection (CR) and immunosuppressant-related side effects; these latter being responsible for a great proportion of the annual graft attrition rate.
Rejection and Immunosuppression
Paolo De Simone;Jessica Bronzoni;
2022-01-01
Abstract
Historically, liver graft rejection has raised great interest in the scientific community since it was the major barrier to successful implementation of liver transplantation (LT) and to the achievement of long-term survival rates. Thanks to discovery and introduction of potent immunosuppressive agents—namely calcineurin inhibitors (CNI), cyclosporine (CsA), and tacrolimus (TAC)—, control of acute rejection (AR) of the liver graft has become feasible, and current clinical focus has shifted to chronic rejection (CR) and immunosuppressant-related side effects; these latter being responsible for a great proportion of the annual graft attrition rate.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
